Press Releases Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 14:08:10 09/02/2026 GMT			5-day change	1st Jan Change
23.32 ^EUR	+1.41%		+2.41%	-8.59%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Press Releases

01-14	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
01-13	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
01-13	Formycon AG: Active Ownership Fund SICAV SIF SCS, sell	EQ
12-24	Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)	AQ
12-23	FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner	EQ
12-09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	AQ
12-09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	EQ
12-04	Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region	EQ
11-28	Formycon Announces New Dupilumab Biosimilar Candidate	AQ
11-24	NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy	EQ
11-20	Ranibizumab Biosimilar Epruvy® launched in Germany	EQ
11-17	Milestone achieved with FYB208: Biosimilar candidate for Dupixent® (dupilumab) as another growth driver in Formycon’s portfolio	PU
11-17	Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio	EQ
11-13	Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025	EQ
30/10/25	Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025	EQ
21/10/25	Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe	EQ
16/10/25	Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America	EQ
08/10/25	AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ
02/10/25	Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron	EQ
30/09/25	NVR: Formycon AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
17/09/25	Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®	EQ
13/08/25	Formycon : Half-Year-Report 2025	PU
13/08/25	Formycon confirms full-year guidance following business development in line with plan – working capital raised	EQ
07/08/25	European Biosimilar Updates – Formycon's Ustekinumab And Alvotech's Cetrolizumab Pegol	AQ
31/07/25	NVR: Formycon AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Press Releases

Filters